3d printer
New 3D printer from Nano Dimension boosts high-res stem cells production


New 3D printer from Nano Dimension boosts high-res stem cells production

Nano Dimension is a 3D printing firm from Israel. It has been recently labelled as a “Cool Vendor in 3D Printing” by famed US research firm, Gartner Inc.

Stem cells creation using 3D printing isn’t something new, however being able to produce high-res stem cells quickly, and in bulk, is definitely something new and interesting. An Israeli 3D printing firm, going by the name Nano Dimension, has successfully developed a new kind of 3D printer that can accelerate the process of stem cell printing.

The successful test carried out by Nano Dimension using a 3D bioprinter in collaboration with Accellta Ltd., another Israeli firm specializing in biotech, opens up a new doors for the 3D printing of large organs and tissues.

Nano Dimension and Accellta

Logos of Nano Dimension and Accellta.

The new test carried out collectively by the Israeli duo, Nano Dimension and Accellta, evinces that both firms have successfully developed a co-op technique for producing living cellular products, capable to boost the mass-production of stem cells at the same time.

3D printing is also known as Additive Manufacturing (AM). The methodology was introduced in the 80s, and deploys multiple processes to synthesize a three-dimensional object.

3D Printer

Close-up of a 3D printer.

With the undertaking, both companies are looking forward for further developing business relations among themselves. Nano Dimension praised its ally, in the successful 3D bioprinting accomplishment, by stating,

“Accellta’s technology can deliver large quantities of high quality cells which can be an enabler for printing even large and complex tissues and organs.”

The bioprinting market is expected to see an immense growth ahead in time. According to a prediction made by popular market research firm IDTechEx, the bioprinting market was evaluated at $481 mn in 2014 which is going to increase its worth nearly 12 times to a total sum of $6 bn by 2024.

There are several niches for bioprinting, such as cosmetics safety testing, pre-clinical drug discovery, tissue printing, and a lot other including the far-fetched organs on chips concept.

3D Bioprinting

Three-dimensional bioprinting of thick vascularized tissues.

Nano Dimension CEO Amit Dror said that the blend of his company’s high speed ink jet capabilities with stem cell suspension technologies from Accellta, will turn out to be a double-treat for the young 3D bioprinting field.

Does Dror’s statement suggests that we’ll soon be able to 3D-print fairly larger and complex tissues – and organs too – which can eventually replace animal tissues? Maybe!

What do you think?